New hope for Hard-to-Treat lung cancer: drug cocktail targets resistant tumors

NCT ID NCT06495125

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) in people with a specific type of advanced lung cancer (LKB1-mutant adenocarcinoma) that has stopped responding to standard treatment. The goal is to see if this triple therapy can shrink tumors or slow cancer growth. About 50 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LUNG ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED LUNG ADENOCARCINOMA REFRACTORY LUNG ADENOCARCINOMA STAGE III LUNG CANCER AJCC V8 STAGE IV LUNG CANCER AJCC V8

Contacts and locations

Locations

Emory Saint Joseph's Hospital
RECRUITING

Atlanta, Georgia, 30342, United States
Emory University Hospital Midtown
NOT_YET_RECRUITING

Atlanta, Georgia, 30308, United States
Emory University Hospital/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.